 2013 Genentech USA, Inc. All rights reserved. Disclosure/Disclaimer The Molecular Basis of Breast Cancer slide presentation is not an independent educational.

Slides:

Advertisements

Similar presentations

1Kitasato-Harvard Symposium 10/03/2002 New Monoclonal Antibody Approved for Advanced Breast Cancer Shin-ichi Nihira, Ph.D. Dept. Clinical Research 3 Chugai.

Advertisements

Alterations in the Cell Cycle and Gene Mutations that Cause Cancer

 2013 Genentech USA, Inc. All rights reserved. Disclosure/Disclaimer The Molecular Basis of Gliomas slide presentation is not an independent educational.

 2013 Genentech USA, Inc. All rights reserved. Disclosure/Disclaimer The Molecular Basis of Colorectal Cancer slide presentation is not an independent.

 2013 Genentech USA, Inc. All rights reserved. Disclosure/Disclaimer The Molecular Basis of Cancer (MBoC): Fundamental and Evolving Concepts slide presentation.

Medical Genetics & Genomics Guri Tzivion, PhD Extension 506 BCHM 560: January 2015 Windsor University School of Medicine.

 2014 Genentech USA, Inc. All rights reserved. 1 Disclosure/Disclaimer The Molecular Basis of Cancer Educational Series is not intended to promote any.

 2013 Genentech USA, Inc. All rights reserved. Disclosure/Disclaimer The Molecular Biomarkers in Cancer (MBiC) slide presentation is not an independent.

Clinical developmentDiscovery Typical development timeline Typically – 8 yearsTypically 7 years.

Dr MOHAMED FAKHRY MOLECULAR BASIS OF CANCER.

BRF Begin with BRAF Searching for a target in metastatic melanoma?

Molecular Pathology – Cell cycle Dr. Leonard Da Silva Senior Lecturer Molecular & Cellular Pathology.

BRCA1 The First Breast Cancer Gene Presentation By Liz Mosley.

KRAS testing in colorectal cancer: an overview. 2 What is KRAS? KRAS is a gene that encodes one of the proteins in the epidermal growth factor receptor.

Cell Signaling Lecture 10. Receptor Tyrosine Kinases Regulate cell proliferation, differentiation, cell survival and cellular metabolism The signaling.

 2014 Genentech USA, Inc. All rights reserved. 1 Disclosure/Disclaimer The Molecular Basis of Cancer Educational Series is not intended to promote any.

 2013 Genentech USA, Inc. All rights reserved. Disclosure/Disclaimer The Molecular Basis of Lung Cancer slide presentation is not an independent educational.

Targeted Therapy: A Giant Step Forward

2012 Navigating Hormonal Therapy Paula D. Ryan, MD, PhD Associate Professor, Medical Oncology April 29, 2012.

Clinical Division of Oncology Department of Medicine I Medical University of Vienna, Austria Monoclonal antibodies in solid tumors.

 2013 Genentech USA, Inc. All rights reserved. Disclosure/Disclaimer The Molecular Basis of Hematological Malignancies slide presentation is not an independent.

Assistant Professor of Medicine Dana-Farber Cancer Institute

Student Research Interest HER2 Receptor Signaling in Breast Cancer Cells Marc Y. Fink Biomedical Sciences LIU-Post.

Esophagogastric Cancer: CMET as a Novel Target David H. Ilson, M.D., Ph.D. GI Oncology Service Memorial Sloan-Kettering Cancer Center New York, NY.

Jo Anne Zujewski, MD Cancer Therapy Evaluation Program Division of Cancer Diagnosis and Treatment National Cancer Institute May 2011 Breast Cancer Biology.

Hormonal Agents Estrogen & Androgen Inhibitors Gonadotropin-Releasing Hormone Agonists Aromatase Inhibitors Tamoxifen Leuprolide Aminogluthethimide.

Cancer --an Overview  Cell Division  Hormones and Cancer  Malignant Transformation  Angiogenesis and Metastasis  Growth.

Gene Transcription G0G0 G1G1 Priming S G2G2 M Cell Cell Cycle Growth Factors + Growth Factors & Cell Cycle Receptors.

Introduction The effects of HER2 gene and receptor overexpression on breast cancer. Prognosis and treatment of HER2+ breast cancer. (See figure 1)

Computational biology of cancer cell pathways Modelling of cancer cell function and response to therapy.

 Angiogenesis Signaling Cascades EGFR PI3K MAPK Nucleus Gene Activation Cell Cycle Progression M G1G1 S G2G2 Fos P P MAPK = mitogen-activated protein.

Genetics of Cancer Genetic Mutations that Lead to Uncontrolled Cell Growth.

Overview of Targeted Therapy Mechanisms November 11, 2011 Targeted Therapies and Biological Therapies SIG.

Prognostic and Predictive Factors: Current Evidence for Individualized Therapy Predictive Molecular Markers: Hormone Receptor Status Presented by Kathleen.

Genetics of Cancer Genetic Mutations that Lead to Uncontrolled Cell Growth.

Extracellular Environment. Extracellular Environment.

A Discussion on Biologic Agents in Gastric Cancer Treatment Yoon-Koo Kang, MD Professor of Medicine Asan Medical Center University of Ulsan College of.

Negative regulation of cell cycle by intracellular signals Checkpoint p53 detects DNA damage & activates p21 p21 inhibits cdk2-cyclinA Intracellular Regulation.

Cancer. Cancer is a disease of the cell cycle Caused by one or more of the following: Increase in growth signals Loss of inhibitory signals In addition,

Date of download: 7/5/2016 Copyright © 2016 McGraw-Hill Education. All rights reserved. Insulin signaling pathways. The insulin signaling pathways provide.

Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non- small cell lung cancer: Focus on epidermal growth factor receptor.

Lung Cancer Tumour Markers

Genetics In Breast Cancer

Targeting signal transduction

The Genetic Basis of Cancer

Alterations in the Cell Cycle and Gene Mutations that Cause Cancer

ד"ר אלה עברון אונקולוגיה ומכון השד אסף הרופא

Fibroblast Growth Factor 3 (FGF3) int-2

Sustaining Proliferative Signaling and Evading Growth Suppressors

Aspirin use and endometrial cancer risk and survival

B lymphocytes produce antibodies.

PTEN (a.k.a. MMAC1 and TEP1) and Cowden’s Disease

Figure 4 Possible combination therapies CDK4/6 inhibitors

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 A schematic representation of the HER2 signalling pathway

PTEN Tumor Suppressor Extraordinaire

Targeted Therapies in Melanoma: Translational Research at Its Finest

PTEN Tumor Suppressor and Cancer

Schematic view of Trk receptors signalling, showing the three major pathways involved in cell differentiation and survival. Schematic view of Trk receptors.

Nat. Rev. Urol. doi: /nrurol

BRAF Alterations as Therapeutic Targets in Non–Small-Cell Lung Cancer

Specific Tumor Suppressor Genes

Simon Ekman, MD, PhD, Murry W. Wynes, PhD, Fred R. Hirsch, MD, PhD

Platelet-derived growth factor (PDGF) signalling pathway.

BC Basics 2017.

Signalling pathways and involved entities that are unravelling experimental therapeutic targets for TNBC. Depicted molecular landscape of TNBC confers.

Brief Review – Growth Factors and Receptors

Connections between insulin/insulin-like growth factor 1 signaling and metabolic pathways in tumor cells. Connections between insulin/insulin-like growth.

Presentation transcript:

 2013 Genentech USA, Inc. All rights reserved. Disclosure/Disclaimer The Molecular Basis of Breast Cancer slide presentation is not an independent educational program, and no CME credits will be provided. This program is not intended to promote any cancer agent or class approved by the FDA/EMA or currently under clinical development. The contents of this slide presentation are owned solely by Genentech; any unauthorized uses are prohibited. This program is presented on behalf of Genentech and the information presented is consistent with FDA guidelines. The following slides are selected samples from a complete presentation. They are for educational purposes only. BIO

 2013 Genentech USA, Inc. All rights reserved. Granulosa Sex hormone biology and its role in breast carcinoma Adrenal glands ESTRONE ESTRADIOL Corpus luteum Ovaries PREMENOPAUSAL POSTMENOPAUSAL Breast adipose tissue AROMATASEAROMATASE Breast Periphery AROMATASE (peripheral) ANDROSTENEDIONE Fabian CJ. Int J Clin Pract. 2007;61:

 2013 Genentech USA, Inc. MBoC Program HER2 protein expression measured by IHC IHC 0IHC 1+IHC 2+IHC 3+ HER2 expression and prognosis in breast cancer Shortened median survival in patients with HER2 overexpression (combined adjuvant and metastatic): HER2+ 2 to 3 years HER2 normal 6 to 7 years HER=human epidermal growth factor receptor; IHC=immunohistochemistry. Andrulis IL, et al. J Clin Oncol. 1998;16: Ellis CM, et al. J Clin Pathol. 2005;58: Banerjee R, et al. J Pharmacol Exp Ther. 2010;334:9-20. Images courtesy of Genentech. 3

 2013 Genentech USA, Inc. MBoC Program 4 BRCA1 and BRCA2 have important roles in DNA repair DNA damage Cancer Failed repair of checkpoint genes Accumulation of mutations Cell-cycle progression despite damage Mutations in BRCA1 or BRCA2 BRCA=breast cancer. Venkitaraman AR. J Cell Sci. 2001; 114: BRCA2 RAD51 BRCA1 Germline mutations in BRCA1 and BRCA2 genes predispose women to an increased risk of breast and ovarian cancers. References: Venkitaraman AR. Functions of BRCA1 and BRCA2 in the biological response to DNA damage. J Cell Sci. 2001;114: Notes

 2013 Genentech USA, Inc. All rights reserved. 5 HER3 The HER2 signaling pathway and anti-HER2 monoclonal antibodies Cell-cycle control Proliferation ↑ Survival Ras Sos Grb2 Shc MEK Angiogenesis Raf Cyclin D1p27BAD GSK3  NFκB mTOR MAPK ↓ Apoptosis Akt PDK1 PI3K HER=human epidermal growth factor receptor; Ras=rat sarcoma; Sos=son of sevenless; Grb2=growth factor receptor-bound 2; PI3K=phosphatidylinositol 3-kinase; PDK=phosphoinositide-dependent kinase; PTEN=phosphatase and tensin homolog; Raf=rapidly accelerating fibrosarcoma; MEK=mitogen-activated protein kinase kinase; MAPK=mitogen-activated protein kinase; mTOR=mammalian target of rapamycin; BAD=Bcl-2–associated death promoter; NFκB=nuclear factor kappa–light-chain-enhancer of activated B-cells; GSK=glycogen synthase kinase. Adjei AA, Hidalgo M. J Clin Oncol. 2005;23: PTEN HER2 HER3 Domain IV A strategy to stem proliferative signaling in cancer cells is to target the extracellular region of growth receptors with monoclonal antibodies. Reference: Adjei AA, Hidalgo M. Intracellular signal transduction pathway proteins as targets for cancer therapy. J Clin Oncol. 2005;23:5386-5403. Notes